PMID- 32390845
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 11
DP  - 2020
TI  - Ginsenoside Rg3 Alleviates ox-LDL Induced Endothelial Dysfunction and Prevents 
      Atherosclerosis in ApoE(-/-) Mice by Regulating PPARgamma/FAK Signaling Pathway.
PG  - 500
LID - 10.3389/fphar.2020.00500 [doi]
LID - 500
AB  - The initiation of atherosclerosis (AS) induced by dyslipidemia is accompanied by 
      endothelial dysfunction, including decreased healing ability and increased 
      recruitment of monocytes. Studies showed ginsenoside Rg3 has potential to treat 
      diseases associated with endothelial dysfunction which can protects against 
      antineoplastic drugs induced cardiotoxicity by repairing endothelial function, 
      while the effect and mechanism of Rg3 on dyslipidemia induced endothelial 
      dysfunction and AS are not clear. Therefore, we investigated the effects of Rg3 
      on oxidized low-density lipoprotein (ox-LDL) induced human umbilical vein 
      endothelial cells (HUVECs) dysfunction and high-fat diets (HFD) induced 
      atherosclerosis in ApoE(-/-) mice, as well as the mechanism. For in vitro assay, 
      Rg3 enhanced healing of HUVECs and inhibited human monocytes (THP-1) adhesion to 
      HUVECs disturbed by ox-LDL, down-regulated focal adhesion kinase (FAK)-mediated 
      expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular 
      adhesion molecule 1 (ICAM-1); restrained the FAK-mediated non-adherent dependent 
      pathway containing matrix metalloproteinase (MMP)-2/9 expression, activation of 
      nuclear factor-kappa B (NF-kappaB), high mRNA levels of monocyte chemotactic protein 
      1 (MCP-1) and interleukin 6 (IL-6), besides Rg3 up-regulated peroxisome 
      proliferators-activated receptor gamma (PPARgamma) in ox-LDL-stimulated HUVECs. GW9662, 
      the PPARgamma-specific inhibitor, can repressed the effects of Rg3 on 
      ox-LDL-stimulated HUVECs. For in vivo assay, Rg3 significantly reduced 
      atherosclerotic pathological changes in ApoE(-/-) mice fed with HFD, up-regulated 
      PPARgamma, and inhibited activation FAK in aorta, thus inhibited expression of 
      VCAM-1, ICAM-1 in intima. We conclude that Rg3 may protect endothelial cells and 
      inhibit atherosclerosis by up-regulating PPARgamma via repressing FAK-mediated 
      pathways, indicating that Rg3 have good potential in preventing dyslipidemia 
      induced atherosclerosis.
CI  - Copyright (c) 2020 Geng, Fu, Yu, Lu, Liu, Sun, Yu, Li, Fu, Xu and Sui.
FAU - Geng, Jianan
AU  - Geng J
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Fu, Wenwen
AU  - Fu W
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Yu, Xiaofeng
AU  - Yu X
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Lu, Zeyuan
AU  - Lu Z
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Liu, Yanzhe
AU  - Liu Y
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Sun, Mingyang
AU  - Sun M
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Yu, Ping
AU  - Yu P
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Li, Xin
AU  - Li X
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Fu, Li
AU  - Fu L
AD  - Institute of Traditional Chinese Medicine Innovation, Jilin Yatai Pharmaceutical 
      Co., Ltd., Changchun, China.
AD  - Institute of Dalian Fusheng Natural Medicine, Dalian Fusheng Pharmaceutical Co., 
      Ltd., Dalian, China.
FAU - Xu, Huali
AU  - Xu H
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
FAU - Sui, Dayun
AU  - Sui D
AD  - Department of Pharmacology, School of Pharmaceutical Sciences, Jilin University, 
      Changchun, China.
LA  - eng
PT  - Journal Article
DEP - 20200422
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC7188907
OTO - NOTNLM
OT  - ApoE-/- mice
OT  - atherosclerosis
OT  - focal adhesion kinase
OT  - ginsenoside Rg3
OT  - monocyte adhesion
OT  - peroxisome proliferators-activated receptor gamma
EDAT- 2020/05/12 06:00
MHDA- 2020/05/12 06:01
PMCR- 2020/04/22
CRDT- 2020/05/12 06:00
PHST- 2019/08/26 00:00 [received]
PHST- 2020/03/30 00:00 [accepted]
PHST- 2020/05/12 06:00 [entrez]
PHST- 2020/05/12 06:00 [pubmed]
PHST- 2020/05/12 06:01 [medline]
PHST- 2020/04/22 00:00 [pmc-release]
AID - 10.3389/fphar.2020.00500 [doi]
PST - epublish
SO  - Front Pharmacol. 2020 Apr 22;11:500. doi: 10.3389/fphar.2020.00500. eCollection 
      2020.